Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Investing Activities (2017 - 2025)

Historic Cash from Investing Activities for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to $13.8 million.

  • Aclaris Therapeutics' Cash from Investing Activities rose 39481.22% to $13.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.7 million, marking a year-over-year decrease of 29139.38%. This contributed to the annual value of -$69.8 million for FY2024, which is 25094.98% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' Cash from Investing Activities stood at $13.8 million, which was up 39481.22% from $5.0 million recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' Cash from Investing Activities registered a high of $32.5 million during Q3 2023, and its lowest value of -$88.7 million during Q4 2024.
  • Moreover, its 5-year median value for Cash from Investing Activities was $2.7 million (2022), whereas its average is -$7.4 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Cash from Investing Activities skyrocketed by 257329.5% in 2023, and later crashed by 127513.91% in 2024.
  • Aclaris Therapeutics' Cash from Investing Activities (Quarter) stood at -$9.2 million in 2021, then skyrocketed by 129.45% to $2.7 million in 2022, then skyrocketed by 179.42% to $7.6 million in 2023, then tumbled by 1275.14% to -$88.7 million in 2024, then soared by 115.59% to $13.8 million in 2025.
  • Its last three reported values are $13.8 million in Q3 2025, $5.0 million for Q2 2025, and $19.1 million during Q1 2025.